GenScript Biotech

Last updated
GenScript Biotech Corporation
Company type Public
SEHK:  1548
Industry Life sciences
Founded2002 in New Jersey [1]
FoundersFangliang Zhang, Ye Wang, Luquan Wang
Headquarters Piscataway, NJ [2]
Area served
Worldwide
Number of employees
6213 (2022)
Website www.genscript.com

GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a New Jersey-based biotech company. [3] [4] [5] It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang. [6] The company mainly provides life science research application instruments and services. [7] It was listed on the Hong Kong Stock Exchange in 2015. [8] The current rotating CEO of the firm is Shao Weihui, [9] and its main subsidiaries include Legend Biotech, [10] Probio Technology, [11] and Bestzyme. [12]

Outside of the United States, GenScript has established presences in China, Singapore, Japan, the United Kingdom, and the Netherlands, among others. [13] The company's operations are divided into four main segments, CDMO platform, life-science services and products platform, integrated cell therapy platform, and industrial synthetic products platform. [13] In September 2021, the firm and its subsidiary Probio received series A funding from Hillhouse Capital. [14]

History

GenScript was formed in 2002 in New Jersey. In 2004, it set up a research and production base in Nanjing, China. [15] In 2009, the company secured a $15 million investment from KPCB China Fund. [16]

In 2011, the company opened a subsidiary in Japan. In 2013, it established Bestzyme. [15] In the following year, another subsidiary of the firm, Legend Biotech, was founded. [17] In 2015, GenScript went public on the SEHK.

In 2017, the Chinese government accepted Nanjing Legend's application for running clinical trials for its blood cancer treatment, [18] with its IND application approved by the CFDA. [19] In the same year, Legend Biotech USA Inc. and Legend Biotech Ireland Limited, non-wholly owned subsidiaries of GenScript, [20] entered into a collaboration agreement with Janssen Biotech [21] to share CAR-T treatments in the US and China. [22] Subsequently, GenScript fully acquired CustomArray. [23]

In 2020, its subsidiary Probio was launched. [24] In the same year, Genscript collaborated with Duke-NUS Medical School to develop and manufacture a serology test called cPass for the detection of COVID-19. [25] On November 6, the cPass test received emergency use authorization from the US FDA. [26] [27] Prior to that, Legend Biotech was listed on the NASDAQ under the symbol "LEGN". [28]

In 2022, Carvykti, a CAR-T cell therapy developed by Janssen Biotech and Legend Biotech, [24] was approved by the US FDA for the treatment of multiple myeloma in adult patients. [29] In the same year, it opened a protein and gene manufacturing facility in Singapore. [30]

In November 2023, Legend Biotech and Novartis signed an out-license deal to develop and manufacture Legend’s chimeric antigen receptor (CAR-T) therapies, that go after delta-like ligand protein 3 (DLL3) including large cell neuroendocrine carcinoma candidate LB2102. Novartis will pay the New-Jersey-based biotech $100 million upfront, and Legend Biotech will be eligible to receive up to $1.01 billion in clinical, regulatory, and commercial milestone payments and tiered royalties. [31]

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US.

<span class="mw-page-title-main">Chugai Pharmaceutical Co.</span> Japanese pharmaceutical company

Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

Kite Pharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically engineered autologous CAR T cell therapy, a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

Crizanlizumab, sold under the brand name Adakveo among others, is a monoclonal antibody medication that binds to P-selectin. It is a medication used to reduce the frequency of vaso-occlusive crisis in people aged 16 years and older who have sickle cell anemia. It is given by injection into a vein.

Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer.

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

<span class="mw-page-title-main">BioNTech</span> German biotechnology company

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

BeiGene is a global biotechnology company that specializes in the development of drugs for cancer treatment. Founded in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in Asia, North America, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

References

  1. ↑ Venus Feng and Yoojung Lee (May 31, 2018). "Road to Chinese Pharma Riches Runs Through the Bronx, New Jersey". Bloomberg News . Archived from the original on May 16, 2023.
  2. ↑ Dawn Furnas (May 26, 2022). "GenScript, fellow NJ biotech partner on COVID-19 antibody test distribution". NJBIZ. Archived from the original on May 16, 2023.
  3. ↑ Rick Mitchell (January 23, 2023). "Paul Hastings Advises GenScript, Probio on $224 Million Funding". Bloomberg Law . Archived from the original on May 16, 2023.
  4. ↑ Tim Gray (July 13, 2018). "The New Revolution Brought About by Gene Synthesis". The New York Times . Archived from the original on May 16, 2023.
  5. ↑ Kate Knibbs. "The Promise of Antibody Treatments for Covid-19". Wired . May 22, 2020. Archived from the original on May 16, 2023. Wired.com .
  6. ↑ Weijing Zhou. "KPCB invests $15 mln in Jinsite". 21st Century Business Herald. June 20, 2009. Archived from the original on May 17, 2023.
  7. ↑ Yuexiang Zhou (May 10, 2023). "Singapore Strives to Become Asia's Biomedical Hub". Lianhe Zaobao . Archived from the original on May 17, 2023.
  8. ↑ Eric Ng (December 22, 2017). "Genscript's shares jump by a third on US$350m Johnson & Johnson unit tie-up". South China Morning Post . Archived from the original on May 16, 2023.
  9. ↑ "Genscript Biotech Corporation Announces Chief Executive Officer Changes". MarketScreener. December 18, 2022. Archived from the original on June 20, 2023.
  10. ↑ Russell Flannery (Forbes Staff) (June 7, 2020). "Johnson & Johnson Partner's Stock Soars As Investors Embrace China Health, Tech". Forbes . Archived from the original on June 18, 2023.
  11. ↑ Rick Mitchell (April 24, 2023). "Wake Up Call: Kirkland, Cole Schotz Advising Bed Bath & Beyond". Bloomberg Law . Archived from the original on June 17, 2023.
  12. ↑ Stephanie Li (May 31, 2023). "China Digest: Lynk Pharma, Bestzyme Bioengineering securing funding". DealStreetAsia . Archived from the original on June 18, 2023.
  13. 1 2 "GenScript Launches A Protein Manufacturing Facility In Singapore". Lianhe Zaobao . Economic Development Board. January 10, 2023. Archived from the original on June 17, 2023.
  14. ↑ "GenScript and Probio Close Series A Financing with Investment from Hillhouse". Paul Hastings . September 6, 2021. Archived from the original on June 10, 2023.
  15. 1 2 "Handbook of GenScript Biotech (2022 Edition)" (PDF). www.genscript.com. May 24, 2022. Archived (PDF) from the original on December 6, 2022.
  16. ↑ Jonathan Shieber (July 17, 2009). "Kleiner Perkins' Former Front Man In China Starts Fresh". The Wall Street Journal . Archived from the original on June 17, 2023.
  17. ↑ Preetika Rana (August 5, 2018). "How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs". The Wall Street Journal . Archived from the original on May 16, 2023.
  18. ↑ Wei, Jianshu; Guo, Yelei; Wang, Yao; Wu, Zhiqiang; Bo, Jian; Zhang, Bin; Zhu, Jun; Han, Weidong (April 2021). "Clinical development of CAR T cell therapy in China: 2020 update". Cellular & Molecular Immunology. 18 (4): 792–804. doi:10.1038/s41423-020-00555-x. PMC   8115146 . PMID   32999455.
  19. ↑ Wei, Jianshu; Guo, Yelei; Wang, Yao; Wu, Zhiqiang; Bo, Jian; Zhang, Bin; Zhu, Jun; Han, Weidong (April 2021). "Clinical development of CAR T cell therapy in China: 2020 update". Cellular & Molecular Immunology. 18 (4): 792–804. doi:10.1038/s41423-020-00555-x. PMC   8115146 . PMID   32999455.
  20. ↑ "GenScript Biotech Releases Announcement of its Latest Research and Development". MarketScreener. August 5, 2020.
  21. ↑ Arpita Dutt (December 22, 2017). "Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs". Yahoo! Finance . Archived from the original on August 29, 2023.
  22. ↑ Will Ballard (October 10, 2019). "Chinese biotech: from copycat to innovator". Financial Times . ISSN   0307-1766. Archived from the original on August 29, 2023.
  23. ↑ Vince Iral (December 27, 2017). "Genscript Biotech to acquire US genomic sequencing company". S&P Global . Archived from the original on May 17, 2023.
  24. 1 2 Dede Williams (January 25, 2023). "GenScript Raises $224 Million in Fresh Capital". CHEManager. Archived from the original on June 10, 2023.
  25. ↑ Lovelyn Tagalag (May 15, 2020). "GenScript to collaborate with Singapore agency on COVID-19 test". S&P Global . Archived from the original on May 16, 2023.
  26. ↑ "Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection". www.fda.gov. Food and Drug Administration. November 6, 2020. Archived from the original on November 6, 2020.
  27. ↑ Tan, Chee-Wah; Chia, Wan-Ni; Young, Barnaby E.; Zhu, Feng; Lim, Beng-Lee; Sia, Wan-Rong; Thein, Tun-Linn; Chen, Mark I.-C.; Leo, Yee-Sin; Lye, David C.; Wang, Lin-Fa (7 October 2021). "Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors". New England Journal of Medicine . 385 (15): 1401–1406. doi:10.1056/NEJMoa2108453. PMC   8422514 . PMID   34407341.
  28. ↑ Lucinda Shen (June 5, 2020). "ZoomInfo raises nearly $1 billion in its IPO". Fortune . Archived from the original on May 17, 2023.
  29. ↑ Peter Loftus (February 28, 2022). "FDA Approves Cell-Based Multiple Myeloma Therapy Discovered in China". The Wall Street Journal . Archived from the original on May 16, 2023.
  30. ↑ Timothy Goh (February 10, 2022). "GenScript's manufacturing facility boosts S'pore's role in fight against pandemic". The Straits Times . Archived from the original on June 18, 2023.
  31. ↑ Ojha, Shreeyashi (2023-11-15). "Legend & Novartis sign $100m agreement - BioProcess Insider". BioProcess International. Retrieved 2023-11-30.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.